Table 2 – Summary of Efficacy Results of Individual Antidepressants1

Medication/Class Number of Participants SMD [95% CI]
Depressive Symptoms

MAOIs


Continue Reading

105

-0.40 [-0.78, -0.01], p = 0.04

Duloxetine

40

-0.80 [-1.45, -0.16], p = 0.01

Sertraline

205

-0.51 [-0.91, -0.12], p = 0.01

Amitriptyline

138

-0.34 [-0.68, 0], p = 0.05

Negative Symptoms

SSRIs

1,057

-0.25 [-0.43, -0.07], p = 0.006

TeCAs

278

-0.63 [-1.03, -0.24], p = 0.002

Selegiline

116

-0.45 [-0.85, -0.04], p = 0.03

Duloxetine

40

-1.38 [-2.07, -0.68], p = 0.0001

Citalopram

369

-0.31 [-0.52, -0.10], p = 0.003

Fluvoxamine

172

-0.47 [-0.80, -0.14], p = 0.005

Mirtazapine

210

-0.84 [-1.31, -0.36], p = 0.0006

Table 3 – Summary of Safety Results1

Adverse Event Number of Participants/Trials Risk Ratio [95% CI] Number Needed to Treat to Harm [95% CI]

Abdominal Plain

250 participants

1.82 [1.02, 3.26]

20 [12, 100]

Constipation

476 participants

1.70 [1.02, 2.86]

20 [9, 50]

Dizziness

663 participants

1.82 [1.09, 3.05]

20 [12, 100]

Dry Mouth

644 participants

1.43 [1.30, 1.96]

20 [12, 100]

Exacerbation of Psychosis

16 trials

1.03 [0.60, 1.75],

p = 0.92

N/A

Dropouts (any reason)

70 trials

0.98 [0.83, 1.15],

p = 0.82

N/A

AEs with no significant difference: agitation, akathisia, anxiety, appetite changes, blurred vision, chest pain, cramps, drowsiness, ejaculatory issues, flatulence, flu, headache, heartbeat changes, hypertension, insomnia, libido, nausea/vomiting/diarrhea, pain, parkinsonism, pharyngitis, rash, respiratory infection, shortness of breath, tinnitus, tremor, urination, weight gain.